Основная статистика
| CIK | 1681682 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to ENDRA Life Sciences Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER 001-37969 ENDRA LIFE SCIENCES INC. (Exact name of regis |
|
| July 25, 2025 |
As filed with the Securities and Exchange Commission on July 25, 2025 As filed with the Securities and Exchange Commission on July 25, 2025 Registration No. |
|
| July 25, 2025 |
EXHIBIT 10.21 CERTAIN INFORMATION HAS BEEN OMITTED IN ACCORDANCE WITH ITEM 601(B)(10) OF REGULATION S-K BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMISSIONS ARE MARKED [***] ORDER FORM Anchorage Contact Client Contact Name: Raheel Haider Name: Alexander Tokman Email: [***] Email: [***] This MASTER CUSTODY SERVICE AGREEMENT |
|
| July 25, 2025 |
EXHIBIT 10.20 INVESTMENT MANAGEMENT AGREEMENT This Investment Management Agreement, dated as of 15 July 2025 (this “Agreement”), is entered into by and between Endra Life Sciences, Inc., a Delaware corporation with its registered address at 3600 Green Court, Ann Arbor, MI 48105-1570 (the “Client”) and Arca Investment Management, LLC, a Delaware limited liability company (the “Adviser”) (each, a “p |
|
| July 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 23, 2025 ENDRA Life Sciences Inc. |
|
| July 16, 2025 |
As filed with the Securities and Exchange Commission on July 16, 2025 As filed with the Securities and Exchange Commission on July 16, 2025 Registration No. |
|
| July 9, 2025 |
EXHIBIT 4.2 PRE-FUNDED COMMON STOCK PURCHASE WARRANT ENDRA LIFE SCIENCES INC. Warrant Shares: Initial Exercise Date: , 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date he |
|
| July 9, 2025 |
As filed with the Securities and Exchange Commission on July 9, 2025 As filed with the Securities and Exchange Commission on July 9, 2025 Registration No. |
|
| July 9, 2025 |
Form of Underwriting Agreement EXHIBIT 1.1 SHARES OF COMMON STOCK AND PRE-FUNDED WARRANTS (EXERCISABLE FOR SHARES OF COMMON STOCK) OF ENDRA LIFE SCIENCES INC. UNDERWRITING AGREEMENT 2025 Lucid Capital Markets, LLC As the Representative of the Several underwriters, if any, named in Schedule I hereto c/o Lucid Capital Markets, LLC 570 Lexington Avenue, 40th Floor New York, New York 10022 Ladies and Gentlemen: The undersigned, END |
|
| July 9, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 9, 2025 ENDRA Life Sciences Inc. |
|
| July 9, 2025 |
EXHIBIT 4.3 UNDERWRITER COMMON STOCK PURCHASE WARRANT ENDRA LIFE SCIENCES INC. Warrant Shares: Initial Issuance Date: , 2025 THIS UNDERWRITER COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date |
|
| July 9, 2025 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-1 (Form Type) ENDRA Life Sciences Inc. |
|
| July 9, 2025 |
EXHIBIT 99.1 Recent Financial Results Below is a summary of certain preliminary estimates regarding our financial results for the quarter ended June 30, 2025. This preliminary financial information is based upon our estimates and is subject to completion of our financial closing procedures. Moreover, this preliminary financial information has been prepared solely on the basis of information that i |
|
| June 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 11, 2025 ENDRA Life Sciences Inc. |
|
| May 30, 2025 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 27, 2025 ENDRA Life Sciences Inc. |
|
| May 15, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 15, 2025 ENDRA Life Sciences Inc. |
|
| May 15, 2025 |
ENDRA Life Sciences Provides a Business Update and Reports First Quarter 2025 Financial Results EXHIBIT 99.1 ENDRA Life Sciences Provides a Business Update and Reports First Quarter 2025 Financial Results ANN ARBOR, Mich. (May 15, 2025) – ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today provided a business update and reported financial results for the three months ended March 31, 2025. Business Update Incorporating Liver Diagnostics in |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER 001-37969 ENDRA LIFE SCIENCES INC. (Exact name of regi |
|
| May 9, 2025 |
CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO 17 C.F.R. § 200.83 As confidentially submitted to the Securities and Exchange Commission on May 8, 2025. This draft registration statement has not been filed publicly with the Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C |
|
| April 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended: December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37 |
|
| April 2, 2025 |
As filed with the Securities and Exchange Commission on April 2, 2025 As filed with the Securities and Exchange Commission on April 2, 2025 Registration No. |
|
| April 2, 2025 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-8 (Form Type) ENDRA LIFE SCIENCES INC. |
|
| March 31, 2025 |
EXHIBIT 10.9 SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release (this “Agreement”) by and between ENDRA Life Sciences Inc. (hereinafter “Employer”), and Francois Michelon (hereinafter “Executive” and, together with the Employer, the “Parties”), provided to Executive on August 12, 2024, is entered into as of the Effective Date hereof (as defined below). WHEREAS, Executive was em |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended: December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37969 ENDRA Life Scien |
|
| March 31, 2025 |
EXHIBIT 3.1 FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ENDRA LIFE SCIENCES INC. The present name of the corporation is ENDRA LIFE SCIENCES INC. The corporation was incorporated under the name “ENDRA INC.” by the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware on July 18, 2007. This Fourth Amended and Restated Certificate of |
|
| March 31, 2025 |
Services Agreement, dated March 25, 2024, between the Company and Impact Solve, LLC* EXHIBIT 10.12 March 19, 2024 Services Agreement This Financial Services Agreement (“Agreement”) is entered into by and between: a) Impact Solve, LLC (“Impact Solve”), a Washington Limited Liability Company; and b) ENDRA Life Sciences Inc. (“Client”); collectively referred to as (“Parties”). I. TERM 1.1 This Agreement is effective as of March 25, 2024 and shall be effective for a period of six (6) |
|
| March 31, 2025 |
Third Amendment to Lease, dated December 1, 2024, by and between the Company and Green Court LLC EXHIBIT 10.17 THIRD AMENDMENT TO LEASE THIS THIRD AMENDMENT TO LEASE (this “Amendment”) is made and entered into as of this 1st day of December, 2024 (the “Effective Date”) by and between GREEN COURT LLC, a Michigan limited liability company (“Landlord”) and ENDRA LIFE SCIENCES INC. (formerly ENDRA INC.), a Delaware corporation (“Tenant”). Capitalized terms used in this Amendment without definitio |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 31, 2025 ENDRA Life Sciences Inc. |
|
| March 31, 2025 |
EXHIBIT 99.2 ENDRA Life Sciences Announces Enhanced Strategy to Enable the Early Detection and Management of Metabolic Diseases Facilitated by Emerging GLP-1 Therapies Enhanced strategic focus for TAEUS addresses a large, unmet global need for a cost-effective tool for monitoring liver health at the point of patient care ANN ARBOR, Mich. (March 31, 2025) – ENDRA Life Sciences Inc. (NASDAQ: NDRA), |
|
| March 31, 2025 |
ENDRA Life Sciences Inc. Insider Trading Policy EXHIBIT 19 ENDRA LIFE SCIENCES INC. Insider Trading Policy ENDRA Life Sciences Inc. (“ENDRA”) has adopted this Insider Trading Policy (the “Policy”) to promote compliance with federal securities laws by directors, officers, employees and consultants of ENDRA and its affiliates, as well as any immediate family members sharing the household of any of the foregoing (collectively, the “Covered Persons |
|
| March 31, 2025 |
EXHIBIT 99.1 ENDRA Life Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Business Update ANN ARBOR, Mich. (March 31, 2025) – ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the fourth quarter and full-year ended December 31, 2024, and provided a business update. Business Upda |
|
| November 22, 2024 |
ENDRA Life Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement EXHIBIT 99.1 ENDRA Life Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement ANN ARBOR, Mich. (November 22, 2024) – ENDRA Life Sciences Inc. (NASDAQ: NDRA), an innovator of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that it has regained compliance with the minimum bid price requirement set forth by The Nasdaq Stock Market LLC (“Nasdaq”). On November 21, 2024, th |
|
| November 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 22, 2024 ENDRA Life Sciences Inc. |
|
| November 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER 001-37969 ENDRA LIFE SCIENCES |
|
| November 19, 2024 |
Employment Agreement, dated August 13, 2024, by and between the Company and Alexander Tokman* EXHIBIT 10.1 August 13, 2024 Via Email Alexander Tokman Dear Alex: ENDRA Life Sciences Inc. (the “Company”) is pleased to offer you employment on the following terms: 1. Position. Commencing on August 13, 2024 (the “Start Date”), you will be appointed Acting Chief Executive Officer and Chairman of the Board of Directors of the Company (the “Board”), and you will report directly to the Board. This |
|
| November 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER 001-37969 ENDRA LIFE SCIENCES INC. (Exact name of |
|
| November 15, 2024 |
EXHIBIT 99.1 ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update Company accelerated enrollment in global multisite pilot study and significantly reduced operating expenses while refocusing resources to clinical and regulatory deliverables ANN ARBOR, Mich. (November 15, 2024) – ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhance |
|
| November 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 15, 2024 ENDRA Life Sciences Inc. |
|
| November 15, 2024 |
SEC File Number 001-379369 CUSIP Number 29273B500 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 5, 2024 |
EXHIBIT 3.1 STATE OF DELAWARE CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION ENDRA Life Sciences Inc., a corporation duly organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify that: FIRST: The Certificate of Incorporation of the Corporation is hereby amended by deleting the text of the first and second paragraphs of Art |
|
| November 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 4, 2024 ENDRA Life Sciences Inc. |
|
| October 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 28, 2024 ENDRA Life Sciences Inc. |
|
| September 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| September 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| September 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confide |
|
| August 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 28, 2024 ENDRA Life Sciences Inc. |
|
| August 28, 2024 |
EXHIBIT 99.1 ENDRA Life Sciences Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirements ANN ARBOR, Mich. (August 28, 2024) – ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that on August 27, 2024, the Company was notified by The Nasdaq Stock Market LLC (“Nasdaq”) that the Nasdaq Hearings Panel (the “Pan |
|
| August 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 22, 2024 ENDRA Life Sciences Inc. |
|
| August 23, 2024 |
EXHIBIT 99.2 ENDRA Life Sciences Inc. Second Quarter 2024 Financial Results Conference Call Thursday, August 22, 2024, 4:30 PM Eastern CORPORATE PARTICIPANTS Alexander Tokman - Acting Chief Executive Officer Richard Jacroux - Chief Financial Officer Ziad Rouag - Head of Regulatory and Clinical Affairs Michael Thornton - Chief Technology Officer Yvonne Briggs - LHA Investor Relations 1 PRESENTATION |
|
| August 23, 2024 |
EXHIBIT 99.1 ENDRA Life Sciences Reports Second Quarter 2024 Financial Results and Provides a Business Update Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, Mich. (August 22, 2024) – ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), reports financial results for the three and six months ended June 30, 2024, as filed in a Form 10- |
|
| August 16, 2024 |
EXHIBIT 99.1 ENDRA Life Sciences Announces Reverse Stock Split Shares Expected to Begin Trading on Split-Adjusted Basis on August 20, 2024 ANN ARBOR, Mich. (August 16, 2024) – ENDRA Life Sciences Inc. (“ENDRA”) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that it will implement a 1-for-50 reverse stock split of the issued shares of its common stock (th |
|
| August 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 16, 2024 ENDRA Life Sciences Inc. |
|
| August 16, 2024 |
STATE OF DELAWARE CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION EXHIBIT 3.1 STATE OF DELAWARE CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION ENDRA Life Sciences Inc., a corporation duly organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify that: FIRST: The Certificate of Incorporation of the Corporation is hereby amended at the Effective Time by deleting the first paragraph of Artic |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER 001-37969 ENDRA LIFE SCIENCES INC. (Exact name of regis |
|
| August 14, 2024 |
EXHIBIT 3.9 July 31, 2024 To: Holder of Series B Warrants Re: Amendment to Series B Warrants Dear []: Reference is made to the issuance and sale by ENDRA Life Sciences Inc. (the “Company”) of shares of the Company’s common stock and pre-funded warrants to purchase shares of the Company’s common stock, together with Series A warrants to purchase shares of the Company’s common stock and Series B war |
|
| August 14, 2024 |
EXHIBIT 3.8 July 31, 2024 To: Holder of Series A Warrants Re: Amendment to Series A Warrants Dear []: Reference is made to the issuance and sale by ENDRA Life Sciences Inc. (the “Company”) of shares of the Company’s common stock and pre-funded warrants to purchase shares of the Company’s common stock, together with Series A warrants to purchase shares of the Company’s common stock (the “Series A W |
|
| August 13, 2024 |
ENDRA Life Sciences Announces Leadership Changes EXHIBIT 99.1 ENDRA Life Sciences Announces Leadership Changes · Board Member Alexander Tokman appointed as acting CEO bringing 24+ years of global commercial leadership experience · Two additional industry veterans join in key roles including regulatory and clinical affairs and finance ANN ARBOR, Mich. (August 13 , 2024) – ENDRA Life Sciences Inc. (“ENDRA”) (NASDAQ: NDRA), a pioneer of Thermo Acou |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 12, 2024 ENDRA Life Sciences Inc. |
|
| August 9, 2024 |
EXHIBIT 3.1 STATE OF DELAWARE CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION ENDRA Life Sciences Inc., a corporation duly organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify that: FIRST: The Certificate of Incorporation of the Corporation is hereby amended by deleting the first paragraph of Article FOURTH in its entir |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 5, 2024 ENDRA Life Sciences Inc. |
|
| July 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| July 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 15, 2024 ENDRA LIFE SCIENCES INC. (Exact name of registrant as specified in its charter) Delaware 001-37969 26-0579295 (State or other jurisdiction of incorporation) (Commission |
|
| June 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| June 25, 2024 | ||
| June 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| June 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended: December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37969 ENDRA Life Scien |
|
| June 14, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ENDRA Life Sciences Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 29273B302 (CUSIP Number) June 4, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed |
|
| June 14, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ENDRA Life Sciences Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 29273B302 (CUSIP Number) June 4, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| June 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confide |
|
| June 6, 2024 |
ENDRA Life Sciences Announces Pricing of $8.0 Million Public Offering EXHIBIT 99.1 ENDRA Life Sciences Announces Pricing of $8.0 Million Public Offering ANN ARBOR, Mich. (June 4, 2024) – ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announced today that it has priced a public offering with gross proceeds to the Company expected to be approximately $8.0 million, before deducting placemen |
|
| June 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 4, 2024 ENDRA Life Sciences Inc. |
|
| June 5, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-278842 PROSPECTUS 6,107,691 Shares of Common Stock Pre-Funded Warrants to purchase up to 55,430,770 Shares of Common Stock Series A Warrants to purchase up to 61,538,461 Shares of Common Stock Series B Warrants to purchase up to 61,538,461 Shares of Common Stock Placement Agent Warrants to purchase up to 3,076,923 Shares of Common Stock and Up |
|
| June 3, 2024 |
June 3, 2024 VIA FACSIMILE AND EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance Washington, DC 20549 Re: ENDRA Life Sciences Inc. Registration Statement on Form S-1 (Registration No. 333-278842) - Concurrence in Acceleration Request Ladies and Gentlemen: Craig-Hallum Capital Group, LLC (the “Placement Agent”), acting as placement agent on a best-efforts basis in an offer |
|
| June 3, 2024 |
June 3, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Re: Acceleration Request for ENDRA Life Sciences Inc. Registration Statement on Form S-1 (File No. 333-278842) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, ENDRA Life Sciences Inc. (the “Company”) hereby requests that th |
|
| May 31, 2024 |
EXHIBIT 4.2 SERIES A COMMON STOCK PURCHASE WARRANT ENDRA LIFE SCIENCES INC. Warrant Shares: Initial Issuance Date: , 2024 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, including the prior receipt of Sharehol |
|
| May 31, 2024 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-1 (Form Type) ENDRA Life Sciences Inc. |
|
| May 31, 2024 |
As filed with the Securities and Exchange Commission on May 31, 2024 As filed with the Securities and Exchange Commission on May 31, 2024 Registration No. |
|
| May 31, 2024 |
EXHIBIT 4.3 SERIES B COMMON STOCK PURCHASE WARRANT ENDRA LIFE SCIENCES INC. Warrant Shares: Initial Issuance Date: , 2024 THIS SERIES B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, including the prior receipt of Sharehol |
|
| May 20, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 20, 2024 ENDRA Life Sciences Inc. |
|
| May 20, 2024 |
EXHIBIT 99.1 ENDRA Provides Update Following In-person Meeting with FDA Increases clarity for ENDRA on regulatory path forward for TAEUS ANN ARBOR, Mich. (May 20, 2024) – ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announced that it has completed what it considers to be a highly informative pre-submission meeting with the U.S. Food and Drug A |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER 001-37969 ENDRA LIFE SCIENCES INC. (Exact name of regi |
|
| May 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 14, 2024 ENDRA Life Sciences Inc. |
|
| May 14, 2024 |
EXHIBIT 99.1 ENDRA Life Sciences Reports First Quarter 2024 Financial Results and Provides a Business Update Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, Mich. (May 14, 2024) – ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three months ended March 31, 2024 and provided a business upd |
|
| May 10, 2024 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-1 (Form Type) ENDRA Life Sciences Inc. |
|
| May 10, 2024 |
EXHIBIT 10.23 PLACEMENT AGENCY AGREEMENT , 2024 Craig-Hallum Capital Group LLC 222 South Ninth Street, Suite 350 Minneapolis, Minnesota 55402 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), ENDRA Life Sciences Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $ of registered securities of the Company, includ |
|
| May 10, 2024 |
EXHIBIT 4.2 SERIES A COMMON STOCK PURCHASE WARRANT ENDRA LIFE SCIENCES INC. Warrant Shares: Initial Issuance Date: , 2024 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, including the prior receipt of Sharehol |
|
| May 10, 2024 |
EXHIBIT 4.6 LOCK-UP AGREEMENT , 2024 Craig-Hallum Capital Group LLC Acting as Placement Agent of the Offering (as defined below) Re: Placement Agency Agreement, dated as of , 2024 (the “Placement Agency Agreement”), by and between ENDRA Life Sciences Inc. (the “Company”) and Craig-Hallum Capital Group LLC (the “Placement Agent”) Ladies and Gentlemen: Defined terms not otherwise defined in this let |
|
| May 10, 2024 |
Form of Placement Agent Warrant EXHIBIT 4.5 PLACEMENT AGENT’S COMMON STOCK PURCHASE WARRANT ENDRA LIFE SCIENCES INC. Warrant Shares: Initial Issuance Date: , 2024 THIS PLACEMENT AGENT’S COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, the date hereof (the |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 10, 2024 ENDRA Life Sciences Inc. |
|
| May 10, 2024 |
EXHIBIT 4.4 PRE-FUNDED COMMON STOCK PURCHASE WARRANT ENDRA LIFE SCIENCES INC. Warrant Shares: Initial Exercise Date: , 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date he |
|
| May 10, 2024 |
EXHIBIT 99.1 Recent Financial Results Below is a summary of certain preliminary estimates regarding our financial results for the quarter ended March 31, 2024. This preliminary financial information is based upon our estimates and is subject to completion of our financial closing procedures. Moreover, this preliminary financial information has been prepared solely on the basis of information that |
|
| May 10, 2024 |
As filed with the Securities and Exchange Commission on May 10, 2024 As filed with the Securities and Exchange Commission on May 10, 2024 Registration No. |
|
| May 10, 2024 |
EXHIBIT 4.3 SERIES B COMMON STOCK PURCHASE WARRANT ENDRA LIFE SCIENCES INC. Warrant Shares: Initial Issuance Date: , 2024 THIS SERIES B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, including the prior receipt of Sharehol |
|
| May 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 3, 2024 ENDRA Life Sciences Inc. |
|
| April 19, 2024 |
EXHIBIT 4.3 SERIES B COMMON STOCK PURCHASE WARRANT ENDRA LIFE SCIENCES INC. Warrant Shares: Initial Issuance Date: , 2024 THIS SERIES B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, including the prior receipt of Sharehol |
|
| April 19, 2024 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-1 (Form Type) ENDRA Life Sciences Inc. |
|
| April 19, 2024 |
EXHIBIT 4.6 LOCK-UP AGREEMENT , 2024 Craig-Hallum Capital Group LLC Acting as representative to the several underwriters Re: Underwriting Agreement, dated as of , 2024 (the “Underwriting Agreement”), by and between ENDRA Life Sciences Inc. (the “Company”) and Craig-Hallum Capital Group LLC acting as representative (the “Representative”) to the several underwriters (each, an “Underwriter” and colle |
|
| April 19, 2024 |
EXHIBIT 4.4 PRE-FUNDED COMMON STOCK PURCHASE WARRANT ENDRA LIFE SCIENCES INC. Warrant Shares: Initial Exercise Date: , 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date he |
|
| April 19, 2024 |
EXHIBIT 4.2 SERIES A COMMON STOCK PURCHASE WARRANT ENDRA LIFE SCIENCES INC. Warrant Shares: Initial Issuance Date: , 2024 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, including the prior receipt of Sharehol |
|
| April 19, 2024 |
EXHIBIT 4.5 UNDERWRITER’S COMMON STOCK PURCHASE WARRANT ENDRA LIFE SCIENCES INC. Warrant Shares: Initial Issuance Date: , 2024 THIS UNDERWRITER’S COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, the date hereof (the “Initial |
|
| April 19, 2024 |
Form of Underwriting Agreement EXHIBIT 1.1 SHARES OF COMMON STOCK AND PRE-FUNDED WARRANTS (EXERCISABLE FOR SHARES OF COMMON STOCK) SERIES A WARRANTS (EXERCISABLE FOR SHARES OF COMMON STOCK) AND SERIES B WARRANTS (EXERCISABLE FOR SHARES OF COMMON STOCK) ENDRA LIFE SCIENCES INC. UNDERWRITING AGREEMENT , 2024 Craig-Hallum Capital Group LLC, As the Representative of the Several underwriters, if any, named in Schedule I hereto 222 S |
|
| April 19, 2024 |
As filed with the Securities and Exchange Commission on April 19, 2024 As filed with the Securities and Exchange Commission on April 19, 2024 Registration No. |
|
| April 3, 2024 |
ENDRA Life Sciences Inc. 202,020 Shares of Common Stock PROSPECTUS Filed pursuant to Rule 424(b)(5) Registration No. 333-277058 ENDRA Life Sciences Inc. 202,020 Shares of Common Stock This prospectus relates to 202,020 shares of common stock, par value $0.0001 per share (the “common stock”), of ENDRA Life Sciences Inc. that PatentVest, Inc. (“PatentVest” or the “Selling Stockholder”) may sell from time to time in one or more offerings on terms to be de |
|
| April 3, 2024 |
ENDRA Life Sciences Inc. Common Stock PROSPECTUS SUPPLEMENT Filed pursuant to Rule 424(b)(5) (to Prospectus dated April 3, 2024) Registration No. |
|
| April 1, 2024 |
April 1, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Re: Acceleration Request for ENDRA Life Sciences Inc. Registration Statement on Form S-3 (File No. 333-277058) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, ENDRA Life Sciences Inc. (the “Company”) hereby requests that t |
|
| March 28, 2024 |
As filed with the Securities and Exchange Commission on March 28, 2024 As filed with the Securities and Exchange Commission on March 28, 2024 Registration No. |
|
| March 28, 2024 |
Offer Letter, dated June 9, 2021, by and between the Company and Irina Pestrikova EXHIBIT 10.22 June 8, 2021 Ms. Irina Pestrikova ***** ***** Dear Irina: It is with great pleasure that ENDRA Life Sciences offers you the position of Senior Director, Finance, reporting to me. This role will initially be part-time and then evolve to a full-time leadership position. You will be responsible for leading the finance and accounting function as we continue to grow and prepare for commer |
|
| March 28, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 28, 2024 ENDRA LIFE SCIENCES INC. |
|
| March 28, 2024 |
EXHIBIT 4.9 CONSULTING SERVICES AGREEMENT PatentVest will perform certain of the Consulting Services generally described below in the Summary and Schedule. The Original Scope of Consulting Services will be the initial services to be provided by PatentVest and will be conducted in accord with the annual fee. Legal Services will be subject to a separate agreement and are not included herein. These C |
|
| March 28, 2024 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-8 (Form Type) ENDRA LIFE SCIENCES INC. |
|
| March 28, 2024 |
Restricted Stock Agreement, dated November 30, 2023, by and between the Company and PatentVest, Inc. EXHIBIT 4.10 ENDRA LIFE SCIENCES INC. RESTRICTED STOCK AGREEMENT THIS RESTRICTED STOCK AGREEMENT (this “Agreement”) is made as of November 30, 2023 (the “Effective Date”) by and between ENDRA Life Sciences Inc., a Delaware corporation (the “Company”), and PatentVest, Inc. (“Recipient”). The 202,020 shares of the Company’s common stock (“Common Stock”) issued to you pursuant hereto are subject to t |
|
| March 28, 2024 |
EXHIBIT 99.1 ENDRA Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, Mich. (March 28, 2024) – ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reports financial results for the three months and year ended December 31, 2023 a |
|
| March 28, 2024 |
Consulting Agreement, dated October 17, 2023, by and between the Company and Alexander Tokman EXHIBIT 10.21 CONSULTING AGREEMENT This CONSULTING AGREEMENT (“Agreement”), made as of this October 17, 2023 (the “Effective Date”), is entered into by ENDRA Life Sciences Inc., a Delaware corporation (“Company”), and Alex Tokman (“Consultant”). INTRODUCTION The Company desires to retain the services of the Consultant as a consultant to the Company, and the Consultant desires to serve as a consult |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended: December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37969 ENDRA Life Scien |
|
| March 28, 2024 |
As filed with the Securities and Exchange Commission on March 28, 2024 As filed with the Securities and Exchange Commission on March 28, 2024 Registration No. |
|
| March 28, 2024 |
Incentive-Based Compensation Recovery Policy EXHIBIT 97 ENDRA LIFE SCIENCES INC. INCENTIVE-BASED COMPENSATION RECOVERY POLICY 1. Policy Purpose. The purpose of ENDRA Life Sciences Inc. (the “Company”) Incentive-Based Compensation Recovery Policy (this “Policy”) is to enable the Company to recover Erroneously Awarded Compensation in the event that the Company is required to prepare an Accounting Restatement. This Policy is intended to comply |
|
| February 14, 2024 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-3 (Form Type) ENDRA Life Sciences Inc. |
|
| February 14, 2024 |
EXHIBIT 1.2 ENDRA LIFE SCIENCES INC. Common Stock (par value $0.0001 per share) At-The-Market Issuance Sales Agreement February 14, 2024 Ascendiant Capital Markets, LLC 100 Front Street, Suite 300 Jupiter, FL 33477 Ladies and Gentlemen: ENDRA Life Sciences Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Ascendiant Capital Markets, LLC and the other sale |
|
| February 14, 2024 |
EXHIBIT 4.4 INDENTURE between ENDRA Life Sciences Inc. and [] TRUSTEE Dated as of [] Providing for Issuance of Debt Securities in Series Reconciliation and tie between Indenture, dated as of , and the Trust Indenture Act of 1939, as amended. Trust Indenture Act of 1939 Section Indenture Section 310(a)(1) 6.11 (a)(2) 6.11 (a)(3) TIA (a)(4) Not Applicable (a)(5) TIA (b) 6.9; 6.11; TIA 311(a) TIA (b) |
|
| February 14, 2024 |
As filed with the Securities and Exchange Commission on February 14, 2024 As filed with the Securities and Exchange Commission on February 14, 2024 Registration No. |
|
| December 29, 2023 |
Prospectus Supplement dated December 29, 2023 Filed pursuant to Rule 424(b)(3) Registration No. 333-271003 Registration No. 333-271483 PROSPECTUS SUPPLEMENT (To Prospectus dated April 27, 2023) This prospectus supplement, dated December 29, 2023 (the “Supplement”), filed by ENDRA Life Sciences Inc. (the “Company”), modifies and supplements certain information contained in the Company’s prospectus, dated April 27, 2023 (as amended and suppleme |
|
| November 14, 2023 |
EXHIBIT 99.1 ENDRA Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, Mich. (November 14, 2023) – ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reports financial results for the three and nine months ended September 30, 2023 and provides |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER 001-37969 ENDRA LIFE SCIENCES INC. (Exact name of |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 14, 2023 ENDRA LIFE SCIENCES INC. |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER 001-37969 ENDRA LIFE SCIENCES INC. (Exact name of regis |
|
| August 14, 2023 |
Up to $3,800,000 of Common Stock PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (To Prospectus Supplements dated March 30, 2022 and June 21, 2021 and Prospectus dated May 3, 2021) Registration No. |
|
| August 14, 2023 |
EXHIBIT 99.1 ENDRA Life Sciences Submits De Novo Request for its TAEUS® System Liver Fat Application to the U.S. FDA Announces Positive Topline Data from Clinical Studies Comparing TAEUS with MRI-PDFF , ANN ARBOR, Mich. (August 14, 2023) – ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of imaging technologies and Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the submission of a De No |
|
| August 14, 2023 |
EXHIBIT 99.1 ENDRA Life Sciences Reports Second Quarter 2023 Financial Results and Provides a Business Update Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, Mich. (August 14, 2023) – ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three and six months ended June 30, 2023 and provided a b |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 14, 2023 ENDRA Life Sciences Inc. |
|
| August 10, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 9, 2023 ENDRA Life Sciences Inc. |
|
| July 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 25, 2023 ENDRA Life Sciences Inc. |
|
| July 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 25, 2023 ENDRA Life Sciences Inc. |
|
| July 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 6, 2023 ENDRA Life Sciences Inc. |
|
| July 6, 2023 |
EXHIBIT 99.1 ENDRA Life Sciences Announces Adjournment of 2023 Annual Meeting of Stockholders to July 25, 2023 All stockholders of record as of May 12, 2023 who have not yet voted are encouraged to vote ANN ARBOR, Mich. (July 6, 2023) –ENDRA Life Sciences Inc. (NASDAQ: NDRA) (the “Company”), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced its 2023 Annual Meeting of Stock |
|
| July 6, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 6, 2023 ENDRA Life Sciences Inc. |
|
| July 6, 2023 |
Press release of ENDRA Life Sciences Inc., dated July 6, 2023 EXHIBIT 99.1 ENDRA Life Sciences Announces Adjournment of 2023 Annual Meeting of Stockholders to July 25, 2023 All stockholders of record as of May 12, 2023 who have not yet voted are encouraged to vote ANN ARBOR, Mich. (July 6, 2023) – ENDRA Life Sciences Inc. (NASDAQ: NDRA) (the “Company”), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced its 2023 Annual Meeting of Stoc |
|
| May 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| May 24, 2023 | ||
| May 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10‐K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended: December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37969 ENDRA Life Scien |
|
| May 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 15, 2023 ENDRA Life Sciences Inc. |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER 001-37969 ENDRA LIFE SCIENCES INC. (Exact name of regi |
|
| May 15, 2023 |
EXHIBIT 99.1 ENDRA Life Sciences Reports First Quarter 2023 Financial Results and Provides a Business Update Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, Mich. (May 15, 2023) – ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three months ended March 31, 2023 and provided a business upd |
|
| May 2, 2023 |
ENDRA Life Sciences Announces Pricing of Upsized $4.5 Million Public Offering EXHIBIT 99.1 ENDRA Life Sciences Announces Pricing of Upsized $4.5 Million Public Offering ANN ARBOR, Mich. (April 28, 2023) – ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announced today that it has priced an underwritten public offering of 3,750,000 shares of its common stock and warrants to purchase 1,875,000 shar |
|
| May 2, 2023 |
EXHIBIT 99.2 ENDRA Life Sciences Announces Closing of Public Offering and Full Exercise of Underwriter’s Option to Purchase Additional Securities ANN ARBOR, Mich. (May 2, 2023) – ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announced today the closing of its previously announced underwritten public offering of 4,312, |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 27, 2023 ENDRA Life Sciences Inc. |
|
| April 28, 2023 |
As filed with the Securities and Exchange Commission on April 28, 2023 As filed with the Securities and Exchange Commission on April 28, 2023 Registration No. |
|
| April 28, 2023 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-1 (Form Type) ENDRA Life Sciences Inc. |
|
| April 28, 2023 |
3,750,000 Shares of Common Stock and Warrants to Purchase up to 1,875,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-271003 Registration No. 333-271483 PROSPECTUS 3,750,000 Shares of Common Stock and Warrants to Purchase up to 1,875,000 Shares of Common Stock We are offering 3,750,000 shares of our common stock and warrants to purchase up to 1,875,000 shares of our common stock pursuant to this prospectus. The warrants are being offered and sold at the rate o |
|
| April 24, 2023 |
April 24, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| April 24, 2023 |
April 24, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Re: Acceleration Request for ENDRA Life Sciences Inc. Registration Statement on Form S-1 (File No. 333-271003) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, ENDRA Life Sciences Inc. (the “Company”) hereby requests that |
|
| April 19, 2023 |
As filed with the Securities and Exchange Commission on April 18, 2023 As filed with the Securities and Exchange Commission on April 18, 2023 Registration No. |
|
| April 18, 2023 |
Form of Underwriter’s Warrant issued in April 2023 Underwritten Public Offering EXHIBIT 4.1 Underwriter’s Warrant Agreement THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY DAYS FOL |
|
| April 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 18, 2023 ENDRA Life Sciences Inc. |
|
| April 18, 2023 |
EXHIBIT 99.1 Recent Financial Results Below is a summary of certain preliminary estimates regarding our financial results for the quarter ended March 31, 2023. This preliminary financial information is based upon our estimates and is subject to completion of our financial closing procedures. Moreover, this preliminary financial information has been prepared solely on the basis of information that |
|
| April 18, 2023 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-1 (Form Type) ENDRA Life Sciences Inc. |
|
| April 18, 2023 |
As filed with the Securities and Exchange Commission on April 18, 2023 As filed with the Securities and Exchange Commission on April 18, 2023 Registration No. |
|
| March 30, 2023 |
Form of Underwriting Agreement EXHIBIT 1.1 UNDERWRITING AGREEMENT between ENDRA LIFE SCIENCES INC. and NEWBRIDGE SECURITIES CORPORATION Common Stock and Warrants [•], 2023 Newbridge Securities Corporation 1200 North Federal Highway, Suite 400 Boca Raton, Florida 33432 Ladies and Gentlemen: The undersigned, ENDRA Life Sciences Inc., a corporation formed under the laws of the State of Delaware (the “Company”), hereby confirms its |
|
| March 30, 2023 |
As filed with the Securities and Exchange Commission on March 30, 2023 S-1 1 endras1.htm S-1 As filed with the Securities and Exchange Commission on March 30, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ENDRA LIFE SCIENCES INC. (Exact name of registrant as specified in its charter) Delaware 3845 26-0579295 (State or other jurisdiction of incorporati |
|
| March 30, 2023 |
Form of Warrant Agency Agreement EXHIBIT 4.4 WARRANT AGENT AGREEMENT WARRANT AGENT AGREEMENT (this “Warrant Agreement”) dated as of April [●], 2023 (the “Issuance Date”) between ENDRA Life Sciences Inc., a company incorporated under the laws of the State of Delaware (the “Company”), and VStock Transfer, LLC, a California limited liability company (the “Warrant Agent”). WHEREAS, pursuant to the terms of that certain Underwriting A |
|
| March 30, 2023 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-1 (Form Type) ENDRA Life Sciences Inc. |
|
| March 30, 2023 |
Form of Warrant issued in April 2023 Underwritten Public Offering EXHIBIT 4.2 COMMON STOCK PURCHASE WARRANT ENDRA LIFE SCIENCES INC. Warrant Shares: Initial Issue Date: , 2023 Initial Exercise Date: , 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the da |
|
| March 16, 2023 |
Non-Employee Director Compensation Policy, effective January 30, 2023* EXHIBIT 10.6 ENDRA Life Sciences Inc. Non-Employee Director Compensation Policy (Adopted by the ENDRA Life Sciences Inc. Board of Directors, effective January 30, 2023) Members of the Board of Directors (the “Board”) of ENDRA Life Sciences Inc. (the “Company”) who are not employees of the Company or any subsidiary of the Company (“Directors”) shall be paid the following amounts in consideration fo |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended: December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37969 ENDRA Life Scien |
|
| March 16, 2023 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-8 (Form Type) ENDRA LIFE SCIENCES INC. |
|
| March 16, 2023 |
EXHIBIT 21.1 Subsidiaries of the Registrant ENDRA Life Sciences Canada Inc. is a corporation formed under the laws of Ontario, Canada in July 2017 and is wholly owned by the Company. ENDRA Life Sciences Holding B.V. was organized under the laws of The Netherlands on July 27, 2020 and is wholly owned by the Company. ENDRA Life Sciences Ltd. was organized under the laws of the United Kingdom on Augu |
|
| March 16, 2023 |
As filed with the Securities and Exchange Commission on March 16, 2023 As filed with the Securities and Exchange Commission on March 16, 2023 Registration No. |
|
| March 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 14, 2023 ENDRA Life Sciences Inc. |
|
| March 14, 2023 |
EXHIBIT 99.1 ENDRA Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, Mich. (March 14, 2023) – ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three months and year ended December 31, 2022, |
|
| December 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 21, 2022 ENDRA Life Sciences Inc. |
|
| December 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 16, 2022 ENDRA Life Sciences Inc. |
|
| December 19, 2022 |
EXHIBIT 10.1 1 2 |
|
| December 8, 2022 |
Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation EXHIBIT 3.1 STATE OF DELAWARE CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION ENDRA Life Sciences Inc., a corporation duly organized and existing under the General Corporation Law of the State of Delaware (the ?Corporation?), does hereby certify that: FIRST: The Certificate of Incorporation of the Corporation is hereby amended by adding the following paragraph to Article FOURTH thereof, w |
|
| December 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 8, 2022 ENDRA Life Sciences Inc. |
|
| December 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 29, 2022 ENDRA Life Sciences Inc. |
|
| November 14, 2022 |
EXHIBIT 99.1 ENDRA Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, Mich. (November 14, 2022) ?ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS?), today reported financial results for the three and nine months ended September 30, 2022, and provide |
|
| November 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 14, 2022 ENDRA Life Sciences Inc. |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER 001-37969 ENDRA LIFE SCIENCES INC. (Exact name of |
|
| October 17, 2022 |
DEFA14A 1 ny20005397x3defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate b |
|
| October 17, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy |
|
| September 27, 2022 |
Certificate of Designation of the Series C Preferred Stock of the Company, dated September 27, 2022. EXHIBIT 3.1 CERTIFICATE OF DESIGNATIONS OF ENDRA LIFE SCIENCES INC. SERIES C PREFERRED STOCK THE UNDERSIGNED, the President and Chief Executive Officer of ENDRA Life Sciences Inc., a Delaware corporation (hereinafter called the ?Corporation?), DOES HEREBY CERTIFY that the following resolution has been duly adopted by the Board of Directors of the Corporation on September 27, 2022: RESOLVED, that p |
|
| September 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2022 ENDRA Life Sciences Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37969 26-0579295 (State or other jurisdiction of incorporation) (Commis |
|
| September 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 ENDRA Life Sciences Inc. (Exact name of registrant as specified in its charter) Delaware 26-0579295 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No. |
|
| September 27, 2022 |
Certificate of Designations of Series C Preferred Stock EXHIBIT 3.1 CERTIFICATE OF DESIGNATIONS OF ENDRA LIFE SCIENCES INC. SERIES C PREFERRED STOCK THE UNDERSIGNED, the President and Chief Executive Officer of ENDRA Life Sciences Inc., a Delaware corporation (hereinafter called the ?Corporation?), DOES HEREBY CERTIFY that the following resolution has been duly adopted by the Board of Directors of the Corporation on September 27, 2022: RESOLVED, that p |
|
| September 27, 2022 |
PRE 14A 1 ny20005397x1pre14a.htm PRE 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check |
|
| August 15, 2022 |
EXHIBIT 99.1 ENDRA Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, Mich. (August 15, 2022) ? ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS?), today reported financial results for the three and six months ended June 30, 2022, and provided a bu |
|
| August 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 15, 2022 ENDRA Life Sciences Inc. |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER 001-37969 ENDRA LIFE SCIENCES INC. (Exact name of regis |
|
| June 23, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 22, 2022 ENDRA Life Sciences Inc. |
|
| June 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confide |
|
| May 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confide |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER 001-37969 ENDRA LIFE SCIENCES INC. (Exact name of regi |
|
| May 12, 2022 |
EXHIBIT 99.1 ENDRA Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, Mich. (May 12, 2022) ? ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS?), today reported financial results for the three months ended March 31, 2022, and provided a business upda |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 12, 2022 ENDRA Life Sciences Inc. |
|
| May 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confide |
|
| May 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confide |
|
| April 22, 2022 |
PRE 14A 1 endra14a.htm FORM 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preli |
|
| April 21, 2022 |
EXHIBIT 99.1 ENDRA Life Sciences Raises $8.7 Million in Gross Proceeds Through its At-The-Market Facility Extends cash runway into 2023 ANN ARBOR, Mich. (April 21, 2022) ? ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS?), announces that the Company has raised $8.7 million in gross proceeds year-to-date from the sale of common stock through its at-t |
|
| April 21, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 21, 2022 ENDRA Life Sciences Inc. |
|
| March 30, 2022 |
EXHIBIT 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) ENDRA LIFE SCIENCES INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered1 Proposed Maximum Offering Price Per Unit2 Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0 |
|
| March 30, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 30, 2022 ENDRA Life Sciences Inc. |
|
| March 30, 2022 |
Up to $9,360,000 of Common Stock 424B5 1 endra424b5.htm FORM - 424B5 PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (To Prospectus Supplement dated June 21, 2021 and Prospectus dated May 3, 2021) Registration No. 333-254711 Up to $9,360,000 of Common Stock This prospectus supplement amends and supplements the information in our prospectus, dated May 3, 2021 (File No. 333-254711) (the “Base Prospectus”) and the shelf regis |
|
| March 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended: December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37969 ENDRA Life Scien |
|
| March 30, 2022 |
EXHIBIT 4.12 DESCRIPTION OF ENDRA LIFE SCIENCES INC.?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following information is a summary of information concerning the securities of ENDRA Life Sciences Inc. (?Company,? ?we,? ?our,? or ?us?) and does not purport to be complete. It is subject to and qualified in its entirety by reference to our Fourth Amended |
|
| March 30, 2022 |
As filed with the Securities and Exchange Commission on March 30, 2022 S-8 1 endras8.htm S-8 As filed with the Securities and Exchange Commission on March 30, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ENDRA LIFE SCIENCES INC. (Exact name of registrant as specified in its charter) Delaware 26-0579295 (State or other jurisdiction of incorporation or |
|
| March 30, 2022 |
EX-21.1 3 ndraex211.htm SUBSIDIARIES OF THE COMPANY EXHIBIT 21.1 Subsidiaries of the Registrant ENDRA Life Sciences Canada Inc. is a corporation formed under the laws of Ontario, Canada in July 2017 and is wholly owned by the Company. ENDRA Life Sciences Holding B.V. was organized under the laws of The Netherlands on July 27, 2020 and is wholly owned by the Company. ENDRA Life Sciences Ltd. was or |
|
| March 30, 2022 |
EXHIBIT 99.1 ENDRA Life Sciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, Mich. (March 30, 2022) ? ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS?), today reported financial results for the three months and year ended December 31, 2021 |
|
| February 10, 2022 |
EXHIBIT 99.1 ENDRA Life Sciences Provides Update on U.S. Regulatory Strategy for its TAEUS? System New path developed in consultation with the FDA to include limited confirmatory clinical data and provide potential future competitive advantages ANN ARBOR, Mich. (February 9, 2022) ? ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS?), announced today i |
|
| February 10, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 9, 2022 ENDRA Life Sciences Inc. |
|
| January 7, 2022 |
ENDRA Life Sciences Inc. January 2022 Investor Presentation, furnished herewith. EXHIBIT 99.1 |
|
| January 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 5, 2022 ENDRA Life Sciences Inc. |
|
| November 15, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 15, 2021 ENDRA Life Sciences Inc. |
|
| November 15, 2021 |
EXHIBIT 99.1 ENDRA Life Sciences Reports Third Quarter 2021 Financial Results and Provides Business Update Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, Mich. (November 15, 2021) ? ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS?), today reported financial results for the three months ended September 30, 2021 and provided |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER 001-37969 ENDRA LIFE SCIENCES INC. (Exact name of |
|
| August 12, 2021 |
Exhibit 99.1 ENDRA Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, Mich. (August 12, 2021) ? ENDRA Life Sciences Inc. (?ENDRA?) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS?), today reported financial results for the three months ended June 30, 2021 and provided a b |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER 001-37969 ENDRA LIFE SCIENCES INC. (Exact name of regis |
|
| August 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 12, 2021 ENDRA Life Sciences Inc. |
|
| June 21, 2021 |
Up to $20,000,000 of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-254711 PROSPECTUS SUPPLEMENT (To prospectus dated May 3, 2021) Up to $20,000,000 of Common Stock ENDRA Life Sciences Inc. has entered into an At-The-Market Issuance Sales Agreement (the ?Sales Agreement?) with Ascendiant Capital Markets, LLC (the ?Sales Agent?) relating to the offer and sale of up to $20,000,000 of our common stock, par value $ |
|
| June 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 21, 2021 ENDRA Life Sciences Inc. |
|
| June 21, 2021 |
EX-1.1 2 ndraex11.htm UNDERWRITING AGREEMENT Exhibit 1.1 ExENDRA LIFE SCIENCES INC. Common Stock (par value $0.0001 per share) At-The-Market Issuance Sales Agreement June 21, 2021 Ascendiant Capital Markets, LLC 110 Front Street, Suite 300 Jupiter, Florida 33477 Ladies and Gentlemen: ENDRA Life Sciences Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with As |
|
| June 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 9, 2021 ENDRA Life Sciences Inc. |
|
| June 15, 2021 |
Exhibit 99.1 ENDRA Life Sciences Appoints Irina Pestrikova as Senior Director of Finance, Announces Departure of CFO David Wells ANN ARBOR, Mich. (June 15, 2021) ? ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS?), announced the appointment of Irina Pestrikova as Senior Director of Finance and Principal Financial Officer. In this new position, Ms. P |
|
| June 8, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 8, 2021 ENDRA Life Sciences Inc. |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER 001-37969 ENDRA LIFE SCIENCES INC. (Exact name of regi |
|
| May 17, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 17, 2021 ENDRA Life Sciences Inc. |
|
| May 17, 2021 |
Exhibit 99.1 ENDRA Life Sciences Reports First Quarter 2021 Financial Results and Provides Business Update Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, Mich. (May 17, 2021) ? ENDRA Life Sciences Inc. (?ENDRA?) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS?), today reported financial results for the three months ended March 31, 2021 and provided a busi |
|
| April 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [x] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] |
|
| April 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [x] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] |
|
| April 29, 2021 |
ENDRA Life Sciences Inc. 3600 Green Court, Suite 350 Ann Arbor, MI 48105 ENDRA Life Sciences Inc. 3600 Green Court, Suite 350 Ann Arbor, MI 48105 April 29, 2021 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Irene Paik Re: ENDRA Life Sciences Inc. Registration Statement on Form S-3 Filed March 25, 2021 File No. 333-254711 Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, registr |
|
| April 27, 2021 |
Other Events, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 27, 2021 ENDRA Life Sciences Inc. |
|
| March 25, 2021 |
Second Amendment to Lease, dated March 15, 2021, by and between the Company and Green Court LLC Exhibit 10.18 SECOND AMENDMENT TO LEASE THIS SECOND AMENDMENT TO LEASE (this ?Amendment?) is made and entered into as of this 15th day of March, 2021 (the ?Effective Date?) by and between GREEN COURT LLC, a Michigan limited liability company (?Landlord?) and ENDRA LIFE SCIENCES INC. (formerly ENDRA INC.), a Delaware corporation (?Tenant?). Capitalized terms used in this Amendment without definitio |
|
| March 25, 2021 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of the Registrant ENDRA Life Sciences Canada Inc. is a corporation formed under the laws of Ontario, Canada in July 2017 and is wholly owned by the Company. ENDRA Life Sciences Holding B.V. was organized under the laws of The Netherlands on July 27, 2020 and is wholly owned by the Company. ENDRA Life Sciences Ltd. was organized under the laws of the United Kingdom on Augu |
|
| March 25, 2021 |
Exhibit 4.12 DESCRIPTION OF ENDRA LIFE SCIENCES INC.?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following information is a summary of information concerning the securities of ENDRA Life Sciences Inc. (?Company,? ?we,? ?our,? or ?us?) and does not purport to be complete. It is subject to and qualified in its entirety by reference to our Fourth Amended |
|
| March 25, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 25, 2021 ENDRA Life Sciences Inc. |
|
| March 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37969 ENDRA Life Scienc |
|
| March 25, 2021 |
Exhibit 99.1 ENDRA Life Sciences Reports 2020 Fourth Quarter and Full Year Financial Results, Provides Business Update Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, Mich. (March 25, 2021) – ENDRA Life Sciences Inc. (“ENDRA”) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three and twelve months ended December |
|
| March 25, 2021 |
Exhibit 4.9 INDENTURE between ENDRA Life Sciences Inc. and [] TRUSTEE Dated as of [] Providing for Issuance of Debt Securities in Series Reconciliation and tie between Indenture, dated as of , and the Trust Indenture Act of 1939, as amended. Trust Indenture Act of 1939 Section Indenture Section 310(a)(1) 6.11 (a)(2) 6.11 (a)(3) TIA (a)(4) Not Applicable (a)(5) TIA (b) 6.9; 6.11; TIA 311(a) TIA (b) |
|
| March 25, 2021 |
As filed with the Securities and Exchange Commission on March 25, 2021 Registration No. |
|
| March 25, 2021 |
As filed with the Securities and Exchange Commission on March 25, 2021 Registration No. |
|
| March 5, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 5, 2021 ENDRA Life Sciences Inc. |
|
| March 5, 2021 |
Exhibit 99.1 |
|
| February 19, 2021 |
Up to $12,600,000 of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-229090 PROSPECTUS SUPPLEMENT (To prospectus dated February 13, 2019) Up to $12,600,000 of Common Stock ENDRA Life Sciences Inc. has entered into an At-The-Market Issuance Sales Agreement (the “Sales Agreement”) with Ascendiant Capital Markets, LLC (the “Sales Agent”) relating to the offer and sale of up to $12,600,000 of our common stock, par v |
|
| February 19, 2021 |
Exhibit 1.1 ENDRA LIFE SCIENCES INC. Common Stock (par value $0.0001 per share) At-The-Market Issuance Sales Agreement February 19, 2021 Ascendiant Capital Markets, LLC 4 Park Plaza, Suite 1950 Irvine, CA 92614 Ladies and Gentlemen: ENDRA Life Sciences Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Ascendiant Capital Markets, LLC and the other sales ag |
|
| February 19, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 19, 2021 ENDRA Life Sciences Inc. |
|
| February 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 2, 2021 ENDRA Life Sciences Inc. |
|
| January 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 11, 2021 ENDRA Life Sciences Inc. |
|
| January 11, 2021 |
Exhibit 99.1 |
|
| December 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 28, 2020 ENDRA Life Sciences Inc. |
|
| December 21, 2020 |
Exhibit 10.1 AMENDMENT 4 TO THE COLLABORATIVE RESEARCH AGREEMENT BETWEEN GENERAL ELECTRIC COMPANY AND ENDRA LIFE SCIENCES INC. This Amendment 4 to the Collaborative Research Agreement ("Amendment"), effective as of the last date of signing below ("Effective Date"), amends the Collaborative Research Agreement between General Electric ("GE") & ENDRA Life Sciences Inc. ("ENDRA"), which became effecti |
|
| December 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 16, 2020 ENDRA Life Sciences Inc. |
